FARMINGDALE, N.Y., Aug. 25, 2016 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international ultrasonic surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic instruments for spine surgery, neurosurgery and other surgical specialties, hosted a successful BoneScalpel Hands-On Workshop during the Scoliosis Research Society ("SRS") Worldwide Conference, 2016 held in Bali, Indonesia last week. Twenty surgeons attended the workshop and received training on the use of BoneScalpel for various spinal surgery procedures with an emphasis on scoliosis.
The BoneScalpel Hands-On Workshop was co-moderated by Dr. Dohar Tobing, Chief, Department of Orthopedic and Traumatology at Cipto Mangunskusumo Hospital, Jakarta, Indonesia & President of the Indonesian Spine Society and Dr. Ifran Saleh, Department Orthopedic and Traumatology also of Cipto Mangunkusumo Hospital.
The faculty presented information on the clinical applications and benefits of the BoneScalpel as well as recommended techniques for optimum results.
Dr. Dohar Tobing stated, "Excessive bleeding can be a significant complication associated with complex spinal surgery. The BoneScalpel is very helpful in controlling bleeding and also helps reduce complications."
Another of Indonesia's most prominent BoneScalpel surgeons, Dr. Didik Librianto, President of the Indonesian Orthopedic Spine Society, added, "BoneScalpel really helps us improve outcomes especially in more complex cases that are prone to bleeding. In addition to helping reduce blood loss, the BoneScalpel provides additional safety benefits."
Although large, with a population of more than 260 million people, Indonesia's medical device market pays close attention to cost containment. Verdy Kohar, Director of Sigma Karsa Magna, Misonix's distributor for Indonesia, commented, "Surgeons in Indonesia immediately recognize the clinical value of BoneScalpel, however, it is the cost savings that BoneScalpel provides that makes it particularly attractive to our market. We are very pleased to have an opportunity to introduce this innovative and cost-effective new technology to Indonesia."
Scott Ludecker, Senior Vice President, Global Sales and Marketing for Misonix, said, "The BoneScalpel's clinical benefits are most appreciated in very complex cases where control of bleeding is a significant challenge. The treatment of scoliosis is an application where the BoneScalpel's advantage over traditional techniques is obvious. For this reason, Misonix finds scoliosis surgeons to be a consistently receptive audience. The SRS Worldwide Conference in Bali, Indonesia provided Misonix with an ideal opportunity to expose the BoneScalpel to leading scoliosis surgeons, one of the Company's key target clinical markets. The SRS Conference in Bali drew over 125 surgeons from around Asia and the Pacific Rim."
"I'd like to thank our moderators and local distributor, Sigma Karsa Magna, for all of their support this past week at the SRS worldwide conference. BoneScalpel workshops at events like this continue to draw a significant number of conference attendees seeking to learn from their peers how to best utilize the BoneScalpel in their practices. Increased safety, reduced blood loss, and efficiency in the operating room continue to be key referenced benefits of the technology," concluded Mr. Ludecker.
Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used in spine surgery, neurosurgery, orthopedic surgery, wound debridement, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.
Safe Harbor Statement
With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.
SOURCE Misonix, Inc.